Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 2/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664584 | 0.88 | BRD4 (0.43) | DGAT1NPC1 | |
| SCHEMBL4666540 | 0.83 | DGAT1 (0.37) | DGAT1NPC1MEN1KMT2A | |
| Dimethylamine SCHEMBL6021489 | 0.81 | NPC1 (0.37) | DGAT1NPC1 | |
| SCHEMBL30501946 | 0.78 | BRD4 (0.49) | TOP2AMEN1KMT2A | |
| SCHEMBL4666497 | 0.74 | BRD4 (0.47) | NPC1MRGPRX4RXRA | |
| SCHEMBL2750918 | 0.73 | NPC1 (0.44) | NPC1KMT2A | |
| SCHEMBL30501981 | 0.72 | BRD4 (0.48) | NPC1 | |
| SCHEMBL21685223 | 0.72 | DGAT1 (0.36) | DGAT1NPC1MEN1KMT2ADHODH | |
| SCHEMBL15476283 | 0.71 | MEN1 (0.45) | NPC1MRGPRX4MAP4K4MEN1KMT2A | |
| SCHEMBL2749549 | 0.71 | HSD17B10 (0.52) | NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113963-A1 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113963-A1 | Cyclic benzimidazoles | VIP, GIPR, SI | TOP2A 4520/4885DGAT1 3226/4885NPC1 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.